Abstract | OBJECTIVE: METHODS: RESULTS: All teenagers developed their disease during childhood (11.3 ± 2.4 years; 50% boys) and were 17.3 ± 0.8 years old at the time of pitolisant therapy. Pitolisant treatment was increased from 10 to 30 mg (n = 1) and 40 mg (n = 3). The adapted Epworth Sleepiness Score decreased from 14.3 ± 1.1 to 9.5 ± 2.9 (P = 0.03) with pitolisant alone to 7 ± 3.4 when combined with mazindol (n = 1), methylphenidate (n = 1), or sodium oxybate plus modafinil (n = 1). Mean sleep onset latency increased from 31 ± 14 minutes to 36 ± 8 minutes (P = 0.21) on the maintenance of wakefulness test. The severity and frequency of cataplexy were slightly improved. Adverse effects were minor ( insomnia, headache, hot flushes, leg pain, and hallucinations) and transitory, except for insomnia, which persisted in 2 teenagers. The benefit was maintained after a mean of 13 months. CONCLUSIONS:
|
Authors | Clara Inocente, Isabelle Arnulf, Hélène Bastuji, Anne Thibault-Stoll, Aude Raoux, Rubens Reimão, Jian-Sheng Lin, Patricia Franco |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
2012 Mar-Apr
Vol. 35
Issue 2
Pg. 55-60
ISSN: 1537-162X [Electronic] United States |
PMID | 22356925
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Central Nervous System Stimulants
- Histamine Agonists
- Piperidines
- Receptors, Histamine H3
- pitolisant
|
Topics |
- Adolescent
- Cataplexy
(drug therapy, physiopathology)
- Central Nervous System Stimulants
(pharmacology, therapeutic use)
- Drug Inverse Agonism
- Female
- Follow-Up Studies
- Histamine Agonists
(pharmacology, therapeutic use)
- Humans
- Male
- Narcolepsy
(drug therapy, physiopathology)
- Off-Label Use
- Piperidines
(pharmacology, therapeutic use)
- Receptors, Histamine H3
(physiology)
- Sleep Stages
(drug effects, physiology)
|